UBS Downgrades Pharmasset (VRUS) to Neutral
VRUS Hot Sheet
Rating Summary:5 Buy, 10 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
UBS downgrades Pharmasset (Nasdaq: VRUS) from Buy to Neutral.
Traders are shrugging off the UBS downgrade today, and buying shares of Pharmasset. The stock most recently traded at $10.49, up 3%.
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections.
Traders are shrugging off the UBS downgrade today, and buying shares of Pharmasset. The stock most recently traded at $10.49, up 3%.
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Societe Generale Downgrades Baker Hughes (BHI) to Hold
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
Create E-mail Alert Related Categories
DowngradesRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
